Newsletter
Major pharma & alcohol companies lobbied Congress on cannabis (Newsletter: August 6, 2025)
Senate panel slams Schedule I marijuana & psychedelics limitations; PA senator on legalization; MS ibogaine hearing; TX hemp poll; LSD for dog anxiety
Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.
Your support makes Marijuana Moment possible…
Subscribers who value this daily dispatch enough to show their support with a few dollars help us keep doing this. Please chip in and help ensure Marijuana Moment’s continued operations.
https://www.patreon.com/marijuanamoment
/ TOP THINGS TO KNOW
The Senate Appropriations Committee approved a report expressing concerns about how Schedule I status “effectively limits” research on marijuana and other drugs, and noting an “increased interest and need to study psychedelics.”
New House and Senate lobbying reports show that a wide variety of alcohol, pharmaceutical, food, financial and other companies disclosed congressional marijuana- and psychedelics-related policy advocacy last quarter.
A Pennsylvania senator said federal marijuana rescheduling would give “political cover” to Republican lawmakers who are still on the fence about legalizing cannabis in the state.
The Mississippi House and Senate Public Health and Human Services Committees have scheduled a hearing on ibogaine for later this month as the chair of the House panel crafts psychedelics reform legislation he plans to file next session.
A new poll shows that four out of five Texas likely voters support regulating rather than banning hemp-derived THC products—including strong majorities of Republicans, Democrats and independents.
A new case study found that microdosing LSD led to a reduction in a dog’s severe separate anxiety, “with the effect persisting for 1 month posttreatment.”
/ FEDERAL
Customs and Border Protection is being sued for alleged religious discrimination by a woman who says her job offer was rescinded after she disclosed use of ayahuasca.
Sen. Ruben Gallego (D-AZ) touted the Senate Appropriations Committee’s approval of a report encouraging research on medical cannabis as an opioid alternative.
/ STATES
Nevada Gov. Joe Lombardo (R) held a ceremonial bill signing for legislation to make various changes to cannabis rules.
California Gov. Gavin Newsom (D) announced that officials have seized nearly 270,000 pounds of illicit cannabis and eradicated more than 260,000 plants, worth an estimated nearly $480 million since the beginning of this year.
New York’s Assembly majority leader said she didn’t see any problems with regulators’ initial interpretation of marijuana business zoning rules before they reversed themselves.
Former staff members for a Massachusetts psychedelics legalization effort detailed allegations of campaign finance violations in new filings.
Colorado regulators proposed changes to marijuana tax rules.
Missouri regulators published an annual report on the state’s marijuana programs.
Maryland regulators fined a cannabis business over multiple alleged violations.
The Nebraska Medical Cannabis Commission met.
New Jersey regulators published a podcast about local cannabis issues.
The Rhode Island Cannabis Control Commission will meet on Thursday.
—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
/ LOCAL
A judge ruled that a Menominee, Michigan measure to put a cap on the number of marijuana dispensary licenses can stay on the August ballot.
Pennington County and Rapid City, South Dakota police are running compliance checks for hemp-based intoxicating products at retailers.
/ INTERNATIONAL
Australian regulators announced a public consultation on the use of unapproved medical cannabis products.
/ SCIENCE & HEALTH
A review concluded that “cannabis-based products for medicinal use with cannabidiol as the primary active constituent demonstrated improvements in pain, behaviour, and seizures, with no serious adverse events” on cats and dogs.
A study found that “hair contamination could arise in vivo even after short single exposures to cannabis and “light cannabis”, underlining the need for a careful interpretation of results of hair analysis in forensic toxicology.”
/ ADVOCACY, OPINION & ANALYSIS
The Consumer Choice Center’s deputy director authored an op-ed calling out the Drug Enforcement Administration for stonewalling on marijuana rescheduling.
The New York Post editorial board criticized the state’s marijuana legalization law as “feckless.”
/ BUSINESS
Metrc and BioTrack launched a strategic partnership.
Canopy Growth Corporation introduced its Canadian-grown 7ACRES brand in Australia.
PAX launched a new vaporizer device.
Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.
Photo courtesy of Chris Wallis/Side Pocket Images.
